Eli Lilly’s next-generation obesity drug, known as retatrutide, is causing unexpected outcomes in ongoing trials. Instead of struggling to lose weight, several participants are actually facing the opposite problem – they are losing too much weight.
One participant experienced a staggering 22% weight loss in just nine months, a rate much faster than what is typically seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight loss was so significant that researchers had to decrease her dosage of retatrutide. Despite this adjustment, she continued to feel nauseous and eventually started skipping doses on her own.
Another participant, who lost 30% of his weight in eight months, developed a kidney stone. While it is unclear if this was directly related to the weight loss, a recent observational study linked GLP-1 drugs to an increased risk of kidney stones.
A third patient saw a 31% decrease in weight over a similar timeframe and has resorted to consuming calorie-dense foods like peanut butter to prevent further weight loss. He expressed his disbelief at the irony of being in an obesity trial and actively trying to avoid losing more weight.
While these participants, all in their 40s and 50s, have found the drug to be life-changing in terms of weight loss and improved health conditions like knee pain, high cholesterol, and fatty liver disease, they are also grappling with the extreme weight loss effects of the medication.
Despite the challenges they are facing, the participants are grateful for the positive impact the drug has had on their lives. They have not been informed whether they are receiving the actual treatment or a placebo, but based on their significant weight loss, they believe they are part of the treatment group.
The unexpected issue of excessive weight loss in these trial participants sheds light on the potential power of Eli Lilly’s next-generation obesity drug. As further research and trials continue, it will be crucial to monitor and address any unexpected side effects or outcomes that may arise.
